- Home
- PDPA vs OSRHW Comparison
PDPA vs OSRHW Comparison
Compare PDPA & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PDPA | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | 21 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PDPA | OSRHW |
|---|---|---|
| Price | $25.12 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 25.8K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.30 | $0.03 |
| 52 Week High | $26.15 | $0.08 |
Technical Indicators
Market Signals| Indicator | PDPA | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 48.40 |
| Support Level | $25.08 | $0.04 |
| Resistance Level | $25.38 | $0.07 |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 79.22 | 39.22 |
Price Performance
Historical ComparisonAbout PDPA Pearl Diver Credit Company Inc.
PEARL DIVER CREDIT COMPANY INC is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation by investing predominantly in third-party Collateralized Loan Obligation (CLO) equity and mezzanine tranches of predominately U.S.-dollar-denominated CLOs backed by corporate leveraged loans issued mainly to U.S. obligors.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.